Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04106492 · OUTCOME

Phase 1 Cohorts

Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors · Source last updated 2025-11-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
mg/m2 per cycle
Interval / dispersion
Not reported
Time frame
From start of treatment to approximately 12 weeks

What was measured

To determine the Recommended Phase 2 Dose of SQ3370

Analysis population: Dose escalation participants

Groups in this outcome

Dose Escalation Cohort (10 mL SQL70)

Participants will receive 10 mL of SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion and then receive escalating doses of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle. SQ3370: SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin

Dose Escalation Cohort (20 mL SQL70)

Participants will receive 20 mL of SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion and then receive escalating doses of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle. SQ3370: SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose Escalation Cohort (10 mL SQL70)30
Dose Escalation Cohort (20 mL SQL70)8

Reported measurements

Source class 1
Values in mg/m2 per cycle · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Dose Escalation Cohort (10 mL SQL70)1250Not reportedNot reportedNot reportedNot reported
Dose Escalation Cohort (20 mL SQL70)1250Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1250
      2. group Id
        OG001
        value
        1250
denoms
  1. counts
    1. group Id
      OG000
      value
      30
    2. group Id
      OG001
      value
      8
    units
    Participants
description
To determine the Recommended Phase 2 Dose of SQ3370
groups
  1. description
    Participants will receive 10 mL of SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion and then receive escalating doses of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle. SQ3370: SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin
    id
    OG000
    title
    Dose Escalation Cohort (10 mL SQL70)
  2. description
    Participants will receive 20 mL of SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion and then receive escalating doses of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle. SQ3370: SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin
    id
    OG001
    title
    Dose Escalation Cohort (20 mL SQL70)
param Type
NUMBER
population Description
Dose escalation participants
reporting Status
POSTED
time Frame
From start of treatment to approximately 12 weeks
title
Phase 1 Cohorts
type
PRIMARY
unit Of Measure
mg/m2 per cycle

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice